Insider Selling: LeMaitre Vascular, Inc. (NASDAQ:LMAT) Director Sells 939 Shares of Stock

Key Points

• LeMaitre Vascular, Inc. Director John A. Roush sold 939 shares of stock at an average price of $93.49, resulting in a total transaction of $87,787.11 and a 24.36% decrease in his position.
• The company reported $0.60 EPS for the last quarter, exceeding analyst expectations by $0.03, alongside a 15% year-over-year revenue growth to $63.15 million.
• LeMaitre Vascular declared a quarterly dividend of $0.20, with a yield of 0.8%, scheduled for payment on September 4th.

LeMaitre Vascular, Inc. (NASDAQ:LMAT - Get Free Report) Director John A. Roush sold 939 shares of the business's stock in a transaction dated Friday, August 8th. The shares were sold at an average price of $93.49, for a total transaction of $87,787.11. Following the completion of the sale, the director directly owned 2,916 shares of the company's stock, valued at approximately $272,616.84. The trade was a 24.36% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

LeMaitre Vascular Price Performance

Shares of LeMaitre Vascular stock traded down $0.87 on Monday, reaching $95.04. 120,983 shares of the stock were exchanged, compared to its average volume of 189,653. The company has a debt-to-equity ratio of 0.46, a quick ratio of 11.74 and a current ratio of 13.96. The firm has a market cap of $2.15 billion, a PE ratio of 46.14, a P/E/G ratio of 2.47 and a beta of 0.79. The firm's 50 day moving average is $84.56 and its 200-day moving average is $86.34. LeMaitre Vascular, Inc. has a one year low of $71.42 and a one year high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The medical instruments supplier reported $0.60 EPS for the quarter, beating the consensus estimate of $0.57 by $0.03. LeMaitre Vascular had a net margin of 20.08% and a return on equity of 13.67%. The business had revenue of $63.15 million during the quarter, compared to the consensus estimate of $62.48 million. During the same period in the previous year, the business earned $0.52 earnings per share. The company's revenue was up 15.0% on a year-over-year basis. As a group, analysts anticipate that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 4th. Investors of record on Thursday, August 21st will be paid a $0.20 dividend. The ex-dividend date of this dividend is Thursday, August 21st. This represents a $0.80 annualized dividend and a yield of 0.8%. LeMaitre Vascular's dividend payout ratio (DPR) is 38.83%.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on LMAT. Cantor Fitzgerald lifted their price objective on shares of LeMaitre Vascular from $92.00 to $95.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 6th. Barrington Research upgraded shares of LeMaitre Vascular from a "market perform" rating to an "outperform" rating and set a $95.00 price target for the company in a research report on Wednesday, August 6th. Four analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Hold" and an average target price of $98.00.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. First Trust Advisors LP lifted its holdings in shares of LeMaitre Vascular by 52.7% in the second quarter. First Trust Advisors LP now owns 612,028 shares of the medical instruments supplier's stock worth $50,829,000 after acquiring an additional 211,280 shares during the last quarter. Annex Advisory Services LLC increased its position in LeMaitre Vascular by 535.2% during the 2nd quarter. Annex Advisory Services LLC now owns 219,667 shares of the medical instruments supplier's stock worth $18,243,000 after purchasing an additional 185,085 shares in the last quarter. Raymond James Financial Inc. bought a new position in LeMaitre Vascular in the 4th quarter valued at approximately $14,900,000. Millennium Management LLC boosted its position in LeMaitre Vascular by 119.8% in the first quarter. Millennium Management LLC now owns 211,222 shares of the medical instruments supplier's stock valued at $17,722,000 after buying an additional 115,141 shares in the last quarter. Finally, Rockefeller Capital Management L.P. bought a new stake in shares of LeMaitre Vascular during the fourth quarter worth $7,787,000. Institutional investors own 84.64% of the company's stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.